MCO Molecular and Clinical Oncology 2049-9450 2049-9469 D.A. Spandidos MCO-16-2-02486 10.3892/mco.2021.2486 Articles Therapeutic efficacy of lenvatinib for hepatocellular carcinoma with iso-high intensity in the hepatobiliary phase of Gd-EOB-DTPA-MRI KuwanoAkifumi TanakaKosuke YadaMasayoshi NagasawaShigehiro MoritaYusuke MasumotoAkihide MotomuraKenta Department of Hepatology, Iizuka Hospital, Iizuka, Fukuoka 820-8505, Japan Correspondence to: Dr Kosuke Tanaka, Department of Hepatology, Iizuka Hospital, 3-83 Yoshio-machi, Iizuka, Fukuoka 820-8505, Japan ktanakah8@aih-net.com

Abbreviations: HCC, hepatocellular carcinoma; MTA, molecular targeted agent; ICI, immune checkpoint inhibitor; HBP, hepatobiliary phase; EOB-MRI, gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid-enhanced magnetic resonance imaging; LEN, lenvatinib; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; IHC, immunohistochemistry; GS, glutamine synthetase; CTNNB1, catenin β-1; OS, overall survival; PFS, progression-free survival; BCLC, Barcelona Clinic Liver Cancer; PIVKA-II, vitamin K absence or antagonist-II; OATP1B3, organic anion transporting polypeptide 1B3; CI, confidence interval

 02 2022 24 12 2021 16 2 53 07 10 2021 08 12 2021 Copyright: © Kuwano et al. 2020 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Previous studies have reported that hepatocellular carcinoma (HCC) harboring WNT/β-catenin mutations exhibits iso-high intensity by gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA-MRI, i.e. EOB-MRI) during the hepatobiliary phase (HBP), thus indicating that EOB-MRI may help clinicians identify an immune exclusion class, which might not respond to treatment with immune checkpoint inhibitors. The present study analyzed the efficacy of lenvatinib for HCC with iso-high intensity during the HBP of EOB-MRI. Overall, 52 patients who underwent EOB-MRI for 140 HCC nodules were classified into iso-high-intensity and low-intensity groups during the HBP of EOB-MRI. The clinical and histological characteristics, and different responses to treatment of both groups were analyzed. The expression levels of β-catenin and glutamine synthetase, indicative of WNT/β-catenin mutations, were enhanced in the HCC with iso-high-intensity group. Nine patients had iso-high intensity, whereas 43 patients had low intensity. Tumor size was larger, and the levels of antagonist-II or vitamin K absence were higher in the iso-high-intensity group. Furthermore, 3/9 patients in the iso-high-intensity group had objective responses compared with 13/43 patients in the low-intensity group. Disease control was observed in 5/9 patients in the iso-high-intensity group and 26/43 patients in the low-intensity group. Median overall survival was 29.8 months for the iso-high-intensity group compared with 20.8 months for the low-intensity group. In the iso-high-intensity group, the median progression-free survival rate was 6.7 months compared with 5.6 months in the low-intensity group. No differences in best percentage change from baseline tumor size were observed in either group. Although few patients were included in this study, the present findings suggested that the efficacy of lenvatinib was unaffected by signal intensity during the HBP of EOB-MRI.

 hepatocellular carcinoma lenvatinib WNT/β-catenin mutations hepatobiliary phase Gd-EOB-DTPA-MRI Funding: No funding was received. Introduction

A previous study reported 85-90% of cases of primary liver cancer were hepatocellular carcinoma (HCC); globally, the third cause of death related to cancer (1). Recent advances in systemic chemotherapy for advanced HCC, including molecular targeted agents (MTAs) and immune checkpoint inhibitor (ICI) therapies, have improved patient prognosis; however, it is important to select agents appropriate for the personalized treatment of HCC (2-4).

Around 11-37% of HCC cases harbor mutations of WNT/β-catenin that lead to the immune microenvironment lacking immune cell filtration, so called ‘immune exclusion’ or ‘non-inflamed cold’, in HCC (5). Furthermore, HCC with immune exclusion associated with mutations of WNT/β-catenin is resistant to ICI therapies (6-8). Therefore, it is important to identify the subclass of HCC with or without immune exclusion induced by WNT/β-catenin mutations before treatment. Recently, HCC treatment has focused on this subclass classification.

Ideally, mutations of WNT/β-catenin would be identified using a non-invasive technique rather than by liver biopsy. Previous studies demonstrated that HCC harboring mutations of WNT/β-catenin had iso-high intensity during the hepatobiliary phase (HBP) by magnetic resonance imaging enhanced by gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA-MRI, i.e. EOB-MRI) indicating EOB-MRI may help identify an immune exclusion class which might not respond to treatment with immune checkpoint inhibitors (9,10). Around 12-22% of HCCs have iso-high intensity during the HBP of EOB-MRI (11,12). EOB-MRI may be a non-invasive alternative to liver biopsy, which requires a histological method to identify mutations of Wnt/β-catenin.

Previous studies have demonstrated how MTAs affect survival of advanced HCC patients (3). Lenvatinib (LEN) is an oral multikinase inhibitor of vascular endothelial growth factor (VEGF) receptors 1-3, fibroblast growth factor (FGF) receptors 1-4, platelet-derived growth factor (PDGF) receptor α, RET, and KIT (13,14). An international randomized, open-label trial that was performed in multiple centers to investigate the non-inferiority of sorafenib (REFLECT; NCT01761266) reported LEN significantly improved progression-free survival (PFS) compared with sorafenib in patients with previously untreated, metastatic, or unresectable HCC. LEN has been approved for HCC treatment (3).

The therapeutic efficacy of LEN for HCC with mutations of WNT/β-catenin has not been reported. Here, we analyzed LEN efficacy for HCC that may have WNT/β-catenin mutations with iso-high intensity during the HBP of EOB-MRI.

 Materials and methods <sec> <title>Patients

This prospective single-center study analyzed LEN efficacy for HCC that may have WNT/β-catenin mutations with iso-high intensity during the HBP of EOB-MRI. Eighty-one patients received LEN for non-resectable HCC at Iizuka Hospital from May 2018 to February 2021. We excluded 26 patients who did not undergo EOB-MRI within 3 months prior to LEN administration and three patients who were observed for <12 weeks. We evaluated 52 patients by EOB-MRI and of these, we enrolled 140 HCC (Fig. 1). This study was performed according to the Declaration of Helsinki guidelines and was approved by Iizuka Hospital ethics committee (approval no. 18070). All patients gave written informed consent.

 Treatment protocol

Patients received doses of LEN according to body weight (8 mg/day for bodyweight <60 kg, or 12 mg/day for bodyweight ≥60 kg) (Eisai Co., Ltd.). Dose interruption and potential subsequent reduction (to 8 mg/day, 4 mg/day, or 4 mg every other day) were permitted when patients developed LEN-related adverse events. The protocols in the REFLECT trial were prescribed by Eisai Co., Ltd. (3). Common Terminology Criteria for Adverse Events, version 4.0 was used to grade adverse events. Adverse events ≥grade 3 or any unacceptable grade 2 adverse events were a cause for reduced drug dose or interrupted treatment as per guidelines for LEN administration. Following occurrence of an adverse event, LEN dose was reduced or temporarily interrupted until symptoms were grade 1 or 2, as per the Eisai Co., Ltd. guidelines.

 Evaluation of treatment efficacy

Physicians evaluated antitumor responses using modified RECIST v.1.1(15). The disease control rate (DCR) was determined according to complete response (CR), partial response (PR), or stable disease (SD) present for ≥4 months. The objective response rate (ORR) was defined as PR or CR. Each nodule was evaluated according to the top three sized nodules in each case.

 EOB-MRI

Characterization and pretreatment staging for HCC was determined by Gd MRI using a 1.5-T or 3.0-T MR system (Ingeina; Philips Healthcare) using the same protocol. For the dynamic study, 0.1 ml Primovist (0.25 mmol/ml gadoxetic acid; Bayer Schering Pharma) was administered intravenously per kg/bodyweight. The optimal arterial dominant phase, calculated as time of peak enhancement in the abdominal aorta + an additional 10 sec of imaging time (16-22 sec) was achieved using the test injection method with 1.5 ml gadoxetic acid + 8-ml saline flush. Subsequent to imaging during the arterial phase, portal and equilibrium phase images were captured at 20 and 60 sec, respectively, once the previous imaging phase was over. The HBP for all patients was obtained 20 min post-injection.

 Imaging analysis

Four hepatologists performed imaging analysis in a blind fashion without clinicopathological information. Qualitative analysis of HCC with iso-high intensity during the HBP of EOB-MRI was defined by a signal intensity higher than the pre-contrast image.

 Immunohistochemical (IHC) analyses

Liver tumor biopsy samples fixed with 10% formalin were paraffin embedded. Serial sections (5-µm) were sectioned from paraffin blocks of liver tissues and stained with hematoxylin-eosin. The presence of glutamine synthetase (GS) and β-catenin was determined in 14 HCC specimens by IHC with the following primary antibodies: monoclonal mouse anti-human β-catenin (#610153; BD Biosciences; 1/300 dilution) or monoclonal mouse anti-human GS (#GS-6; Millipore; 1/500 dilution). A Bond Polymer System was used to develop reactions (Leica Biosystems) related to secondary antibodies. β-catenin staining in the nucleus is indicative of an activating mutation in the catenin β-1 (CTNNB1) gene (16,17) and strong GS diffuse staining is indicative of the constitutive activation of WNT/β-catenin signaling associated with β-catenin mutations (18). Therefore, the presence of β-catenin nuclear staining in ≥5% of tumor cells (19) or strong diffuse GS staining were considered to demonstrate the activation of WNT/β-catenin signaling (9).

 Statistical analysis

JMP Pro Version 11 statistical software was used for all analyses (SAS Institute, Inc.). Results were shown as the median (inter-quartile range). Significant differences between groups were examined by χ2, Fisher's exact or Mann-Whitney U test. The Kaplan-Meier technique was used for the statistical analyses of overall survival (OS) and PFS; significant differences in OS and PFS were determined by log-rank analysis. Statistical significance was determined when P<0.05.

 Results <sec> <title>Subjects' characteristics

Patient characteristics are shown in Table I. The iso-high-intensity group contained patients with iso-high-intensity and low-intensity nodules. There were nine patients (17.3%) and 14 HCC nodules (10%) with iso-high intensity and 43 patients (82.7%) and 126 HCC nodules (90.0%) with low intensity. Five patients (55.6%) had both iso-high-intensity and low-intensity nodules in the iso-high-intensity group. Tumor size was larger in the iso-high-intensity group vs the low-intensity group [6.2 cm (3.25-8.35) vs. 2.5 cm (1.6-3.9), P=0.004]. The levels of antagonist-II (PIVKA-II) or vitamin K absence were higher in the iso-high-intensity group [938 mAU/ml (26.5-31832.5) vs. 140 mAU/ml (32-18112), P=0.0137]. There were two patients with Barcelona Clinic Liver Cancer (BCLC) stage A, four with stage B, and three with stage C in the iso-high-intensity group. In addition, there were five patients with BCLC stage A, 23 with stage B and 15 with stage C in the low-intensity group. Age, sex, etiology, Child-Pugh grade, microvascular invasion (MVI), extrahepatic spread (HIS), and serum α-fetoprotein levels were similar between groups.

 IHC of β-catenin and GS in HCC tissues

The expressions of β-catenin and GS in 13 patients (four patients in the iso-high-intensity group and nine patients in the low-intensity group) were assessed by IHC before LEN therapy. Typical magnetic resonance images and immunohistochemical findings are presented in Fig. 2A and B. All four patients (100%) were positive for β-catenin or GS staining in the iso-high-intensity group, and 3/9 (33.3%) were positive for β-catenin or GS staining in the low-intensity group (Table II); however, there were no differences in β-catenin (P=1.00) and GS (P=0.07) staining between the two groups because of the small patient numbers in these groups.

 Efficacy of LEN in the iso-high intensity and low-intensity groups

The OS, PFS, ORR, and DCR were similar between groups. The ORR (CR+PR) was 3/9 (33.3%) in the iso-high-intensity group and 13/43 (30.2%) in the low-intensity group (P=0.62). The DCR (CR+PR+SD) was 5/9 (55.6%) in the iso-high intensity group and 26/43 (60.5%) in the low-intensity group (P=0.45) (Table III). Median OS was 29.8 months [95% confidence interval (CI)=7.1-31.3] in the iso-high-intensity group versus 20.7 months (95% CI=11.2-26.3) in the low-intensity group (P=0.84). The median PFS was 6.7 months (95% CI=2.9-11.9) in the iso-high-intensity group compared with 5.6 months (95% CI=3.7-7.9) in the low-intensity group (P=0.95; Fig. 3).

We also evaluated the change in each HCC tumor treated with LEN. The best percentage change was -10.5% in the iso-high-intensity group (4.99±0.44 cm to 4.79±0.54 cm) and 1.1% in the low-intensity group (1.88±0.15 cm to 1.88±0.18 cm; Fig. 4). We compared the values of the best percentage change between groups using Mann-Whitney U test. The best percentage change from the baseline tumor size (P=0.67), the ORR [28.6% (4/14) in the iso-high-intensity group and 27.8% (35/126) in the low-intensity group (P=0.73)], and the DCR [92.9% (13/14) in the iso-high-intensity group and 73.0% (92/126) in the low-intensity group (P=0.39; Table IV)] were similar between groups.

 Discussion

Our current study suggested that the status of mutations of WNT/β-catenin may not influence LEN effectiveness. Approximately 30% of HCC cases were reported to show the constitutive activation of WNT/β-catenin signaling, induced by the relevant gene mutations (20). The negative influence of WNT/β-catenin activation on the DCR and PFS of patients receiving anti-PD-1 therapy (7,8,21). However, the PFS was similar between sorafenib-treated patients with and without mutations in WNT/β-catenin genes who had undergone gene sequencing (10). Although the efficacy of sorafenib and other MTAs might be independent of WNT/β-catenin mutation status, clinical evidence demonstrating how responses of HCC patients to LEN are affected by WNT/β-catenin activation and how an immune cold phenotype is acquired, is still lacking.

WNT/β-catenin pathway activation promotes β-catenin accumulation in the cytoplasm, its nuclear translocation, and diffuse accumulation of GS, a transcriptional target of β-catenin (22-24). The presence of WNT/β-catenin mutations is determined by IHC analysis showing the nuclear expression of β-catenin or cytoplasmic overexpression of GS in HCC tissues, indicating they might be useful biomarkers of WNT/β-catenin mutations (22-24).

Furthermore, GS and β-catenin expressions were reported to correlate with OATP1B3 expression (25) and HCC with WNT/β-catenin mutations showed iso-high intensity during the HBP of EOB-MRI (9,10). The mechanism involves the induction of OATP1B3 (an EOB transporter) by WNT/β-catenin mutations (9,26). Therefore, iso-high intensity during the HBP of EOB-MRI might be useful as an imaging biomarker of HCC patients with mutations of WNT/β-catenin. The frequency of HCCs with iso-high intensity was 12-22% during the HBP of EOB-MRI (11,12). We investigated the immunostaining of β-catenin and GS for the detection of mutations of WNT/β-catenin. Several HCC tissues with iso-high intensity during the HBP of EOB-MRI showed GS or β-catenin positive staining. Thus, we confirmed mutations of WNT/β-catenin in HCC with iso-high intensity during the HBP of EOB-MRI as previously reported (25).

Our findings suggested that the efficacy of LEN did not differ between the iso-high-intensity group, in which patients may have WNT/β-catenin mutations, and the low-intensity group.

Clinical trials or studies using pre-clinical models to investigate immunomodulatory influences of antiangiogenic agents on the tumor microenvironment reported enhanced maturation of dendritic cells, trafficking and function of T cells, and reversed immunosuppression induced by hypoxia or immunosuppressive cells (27-29). Other in vivo and in vitro studies reported sorafenib enhanced antitumor immunity by promoting tumor-associated macrophage polarization to an M1 phenotype (30-32), enhancing the infiltration and functions of CD4+ and CD8+ T cells (33,34), lowering numbers of Tregs (35-37), and reversing suppressive functions of myeloid-derived cells in tumor microenvironments (22,38,39). Other MTAs including LEN were shown to promote antitumor immune activity in pre-clinical models (40-42). Many of these immunomodulatory effects of MTAs might be associated with the inhibition of VEGFR signaling (27). Compared with earlier tyrosine kinase inhibitors, LEN has a greater inhibitory effect on FGFR4(43). WNT/β-catenin mutations are associated with FGFR4 overexpression (43) suggesting the therapeutic effects of MTAs including LEN might not be affected by WNT/β-catenin mutations although they might alter the ‘non-inflamed cold’ subclass to the ‘inflamed hot’ subclass in the immune microenvironment of WNT/β-catenin-mutant HCC.

Fujita et al classified HCCs into one of the three groups on the basis of intensity during the HBP of EOB-MRI: i) homogeneous hypointensity; ii) heterogeneous hyperintensity; and iii) homogeneous hyperintensity (44). During the HBP, all HCCs in the iso-high-intensity group in our study displayed heterogeneous hyperintensity (group 2). The tumor size was larger and PIVKA-II levels were higher in the iso-high-intensity group compared with the low-intensity group, similar to our previous study. Other studies reported that GS-positive HCCs were larger although PIVKA-II levels were not associated to tumor size. Therefore, PIVKA-II levels in the iso-high-intensity group of GS-positive HCCs might be higher than those in the low-intensity group (45,46). Fujita et al recorded a disease-free survival rate in group 2 that was significantly lower compared with group 1(44), but our study revealed the OS, PFS, ORR, and DCR were similar in all groups after LEN treatment.

Study limitations were as follows. First, this study was performed at a single center and therefore had limited numbers of HCC cases. Second, it was unclear whether the mutations of one tumor reflected the mutations in other masses when considering the heterogeneity of HCC in multiple masses. Third, we could not evaluate the frequency of β-catenin mutations in HCC with iso-high intensity or low-intensity during the HBP of EOB-MRI because biopsies were not obtained from all patients. We also had to consider that HCC with low intensity could also be positive for β-catenin or GS.

The results suggested that the efficacy of LEN was similar between the iso-high-intensity and low-intensity groups. Given these limitations, further studies enrolling a larger number of cases is needed before MTAs such as LEN can be used as a first-line treatment for HCC with iso-high intensity instead of ICIs alone or in combination with angiogenesis inhibitors, which are the most common first-line regimens for advanced HCC in many countries (2). These findings might allow us to suggest the early therapeutic evaluation of ICIs alone or in combination with angiogenesis inhibitors for HCC with iso-high intensity and quickly change to MTAs if the initial treatment is ineffective. The findings of this study might allow the personalized treatment of patients with HCC by aiding the selection of appropriate therapeutic agents. However, these findings should be confirmed using a larger number of patients.

 Acknowledgements

The authors would like to acknowledge Mrs. Y. Ishibashi (Department of Hepatology, Iizuka Hospital) for aiding preparation of the text.

 Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

 Authors' contributions

AK, MY, KT, AM and KM designed the study. AK, MY, SN, KT and YM assisted with the data analyses. AK wrote the initial draft of the manuscript. MY and KM contributed to data analysis and interpretation. MY and KM helped prepare the manuscript and critically reviewed the manuscript. AK and KT confirm the authenticity of all the raw data. All authors read and approved the final manuscript.

 Ethics approval and consent to participate

The research and protocol were in accord with the Declaration of Helsinki principles and the ethical guidelines of the 1975 Declaration of Helsinki, respectively. This study received approval from the Iizuka Hospital Ethics Committee (no. 18070). Written informed consent was obtained from all individual participants included in the study.

 Patient consent for publication

Not applicable.

 Competing interests

All authors declare that they have no competing interests.

 References CaldwellSParkSHThe epidemiology of hepatocellular cancer: From the perspectives of public health problem to tumor biologyJ Gastroenterol44 SupplS96S10120091914880110.1007/s00535-008-2258-6 FinnRSQinSIkedaMGallePRDucreuxMKimTYKudoMBrederVMerlePKasebAOAtezolizumab plus bevacizumab in unresectable hepatocellular carcinomaN Engl J Med3821894190520203240216010.1056/NEJMoa1915745 KudoMFinnRSQinSHanKHIkedaKPiscagliaFBaronAParkJWHanGJassemJLenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trialLancet3911163117320182943385010.1016/S0140-6736(18)30207-1 EsoYMarusawaHNovel approaches for molecular targeted therapy against hepatocellular carcinomaHepatol Res4859760720182968963110.1111/hepr.13181 TorbensonMSNgIOParkYNRoncalliMSakamotoMDigestive system tumours: WHO classification of tumours. In: Hepatocellular Carcinoma. 5th edition. WHO Classification of Tumours Editorial Board. WHO Press, Geneva, pp229-239, 2019. SiaDJiaoYMartinez-QuetglasIKuchukOVillacorta-MartinCCastro de MouraMPutraJCampreciosGBassaganyasLAkersNIdentification of an immune-specific class of hepatocellular carcinoma, based on molecular featuresGastroenterology15381282620172862457710.1053/j.gastro.2017.06.007 LlovetJMMontalRSiaDFinnRSMolecular therapies and precision medicine for hepatocellular carcinomaNat Rev Clin Oncol1559961620183006173910.1038/s41571-018-0073-4 PinyolRSiaDLlovetJMImmune exclusion-Wnt/CTNNB1 class predicts resistance to immunotherapies in HCCClin Cancer Res252021202320193061713810.1158/1078-0432.CCR-18-3778 UenoAMasugiYYamazakiKKomutaMEffendiKTanamiYTsujikawaHTanimotoAOkudaSItanoOOATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinomaJ Hepatol611080108720142494628310.1016/j.jhep.2014.06.008 KudoMGd-EOB-DTPA-MRI could predict WNT/β-catenin mutation and resistance to immune checkpoint inhibitor therapy in hepatocellular carcinomaLiver Cancer947949020203308327610.1159/000509554 TsuboyamaTOnishiHKimTAkitaHHoriMTatsumiMNakamotoANaganoHMatsuuraNWakasaKTomodaKHepatocellular carcinoma: Hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging-correlation with expression of sinusoidal and canalicular transporters and bile accumulationRadiology25582483320102050172010.1148/radiol.10091557 KitaoAMatsuiOYonedaNKozakaKKobayashiSKodaWGabataTYamashitaTKanekoSNakanumaYHypervascular hepatocellular carcinoma: Correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR imagesRadiology26578078920122317554310.1148/radiol.12120226 TohyamaOMatsuiJKodamaKHata-SugiNKimuraTOkamotoKMinoshimaYIwataMFunahashiYAntitumor activity of lenvatinib (e7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer modelsJ Thyroid Res201463874720142529521410.1155/2014/638747 YamamotoYMatsuiJMatsushimaTObaishiHMiyazakiKNakamuraKTohyamaOSembaTYamaguchiAHoshiSSLenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverageVasc Cell61820142519755110.1186/2045-824X-6-18 LencioniRLlovetJMModified RECIST (mRECIST) assessment for hepatocellular carcinomaSemin Liver Dis30526020102017503310.1055/s-0030-1247132 HsuHCJengYMMaoTLChuJSLaiPLPengSYBeta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosisAm J Pathol15776377020001098011610.1016/s0002-9440(10)64590-7 Laurent-PuigPLegoixPBluteauOBelghitiJFrancoDBinotFMongesGThomasGBioulac-SagePZucman-RossiJGenetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesisGastroenterology1201763177320011137595710.1053/gast.2001.24798 Zucman-RossiJBenhamoucheSGodardCBoyaultSGrimberGBalabaudCCunhaASBioulac-SagePPerretCDifferential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomasOncogene2677478020071696429410.1038/sj.onc.1209824 TsujikawaHMasugiYYamazakiKItanoOKitagawaYSakamotoMImmunohistochemical molecular analysis indicates hepatocellular carcinoma subgroups that reflect tumor aggressivenessHum Pathol50243320162699743510.1016/j.humpath.2015.10.014 LeeHCKimMWandsJRWnt/Frizzled signaling in hepatocellular carcinomaFront Biosci111901191520061636856610.2741/1933 HardingJJNandakumarSArmeniaJKhalilDNAlbanoMLyMShiaJHechtmanJFKundraREl DikaIProspective Genotyping of hepatocellular carcinoma: Clinical implications of next-generation sequencing for matching patients to targeted and immune therapiesClin Can Res252116212620193037375210.1158/1078-0432.CCR-18-2293 NhieuJTRenardCAWeiYCherquiDZafraniESBuendiaMANuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferationAm J Pathol15570371019991048782710.1016/s0002-9440(10)65168-1 CadoretAOvejeroCTerrisBSouilELévyLLamersWHKitajewskiJKahnAPerretCNew targets of beta-catenin signaling in the liver are involved in the glutamine metabolismOncogene218293830120021244769210.1038/sj.onc.1206118 LoeppenSSchneiderDGaunitzFGebhardtRKurekRBuchmannASchwarzMOverexpression of glutamine synthetase is associated with beta-catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbitalCancer Res6256855688200212384525 KitaoAMatsuiOYonedaNKozakaKKobayashiSSanadaJKodaWMinamiTInoueDYoshidaKHepatocellular carcinoma with β-catenin mutation: Imaging and pathologic characteristicsRadiology27570871720152566851910.1148/radiol.14141315 GilesRHvan EsJHCleversHCaught up in a Wnt storm: Wnt signaling in cancerBiochim Biophys Acta165312420031278136810.1016/s0304-419x(03)00005-2 RamjiawanRRGriffioenAWDudaDGAnti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?Angiogenesis2018520420172836126710.1007/s10456-017-9552-y HegdePSWallinJJMancaoCPredictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeuticsSemin Cancer Biol5211712420182922946110.1016/j.semcancer.2017.12.002 KwilasARDonahueRNTsangKYHodgeJWImmune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapyCancer Cell Microenviron2e67720152600570810.14800/ccm.677 WangDYJohnsonDBDavisEJToxicities associated with PD-1/PD-L1 blockadeCancer J24364020182936072610.1097/PPO.0000000000000296 SprinzlMFReisingerFPuschnikARingelhanMAckermannKHartmannDSchiemannMWeinmannAGallePRSchuchmannMSorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cellsHepatology572358236820132342403910.1002/hep.26328 WeiXTangCLuXLiuRZhouMHeDZhengDSunCWuZMiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinomaOncotarget6183891840520152615876210.18632/oncotarget.4089 FarsaciBDonahueRNCoplinMAGrengaILeponeLMMolinoloAAHodgeJWImmune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccinesCancer Immunol Res21090110220142509277110.1158/2326-6066.CIR-14-0076 RomeroAIChaputNPoirier-ColameVRusakiewiczSJacquelotNChabaKMortierEJacquesYCaillat-ZucmanSFlamentCRegulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: Role of IL-15Rα and NKG2D triggeringCancer Res74688020142419713510.1158/0008-5472.CAN-13-1186 SunayMMFooteJBLeathermanJMEdwardsJPArmstrongTDNirschlCJHicksJEmensLASorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivoInt Immunopharmacol4611212320172828257510.1016/j.intimp.2017.02.028 ChuangHYChangYFLiuRSHwangJJSerial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironmentPLoS One9e10999220142533397310.1371/journal.pone.0109992 ChenMLYanBSLuWCChenMHYuSLYangPCChengALSorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunityInt J Cancer13431933120142381824610.1002/ijc.28362 CabreraRAraratMXuYBruskoTWasserfallCAtkinsonMAChangLJLiuCNelsonDRImmune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinomaCancer Immunol Immunother6273774620132322389910.1007/s00262-012-1380-8 ChangCJYangYHChiuCJLuLCLiaoCCLiangCWHsuCHChengALTargeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinomaInt J Cancer1421878188920182926624510.1002/ijc.31216 KwilasARArdianiADonahueRNAftabDTHodgeJWDual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccineJ Transl Med1229420142538865310.1186/s12967-014-0294-y TsaiAKKhanAYWorgoCEWangLLLiangYDavilaEA multikinase and DNA-PK inhibitor combination immunomodulates melanomas, suppresses tumor progression, and enhances immunotherapiesCancer Immunol Res579080320172877520810.1158/2326-6066.CIR-17-0009 HeineASchillingJGrünwaldBKrügerAGevenslebenHHeldSAGarbiNKurtsCBrossartPKnollePThe induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinibCancer Immunol Immunother6527328220162678687410.1007/s00262-015-1790-5 YamauchiMOnoAIshikawaAKodamaKUchikawaSHatookaHZhangPTeraokaYMorioKFujinoHTumor fibroblast growth factor receptor 4 level predicts the efficacy of lenvatinib in patients with advanced hepatocellular carcinomaClin Transl Gastroenterol11e0017920203267780510.14309/ctg.0000000000000179 FujitaNNishieAKuboYAsayamaYUshijimaYTakayamaYMoirtaKShirabeKAishimaSHondaHHepatocellular carcinoma: Clinical significance of signal heterogeneity in the hepatobiliary phase of gadoxetic acid-enhanced MR imagingEur Radiol2521122020152506339510.1007/s00330-014-3349-9 Dal BelloBRosaLCampaniniNTinelliCTorello VieraFD'AmbrosioGRossiSSiliniEMGlutamine synthetase immunostaining correlates with pathologic features of hepatocellular carcinoma and better survival after radiofrequency thermal ablationClin Cancer Res162157216620102023388210.1158/1078-0432.CCR-09-1978 WeitzICLiebmanHADes-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: A critical reviewHepatology189909971993840637410.1002/hep.1840180434

Patient flow chart. HCC, hepatocellular carcinoma; EOB-MRI, gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid-enhanced magnetic resonance imaging; HBP, hepatobiliary phase.

Typical MR images and immunohistochemical findings. (A) HCC with iso-high-intensity in the HBP of EOB-MRI. (B) HCC with the low-intensity in the HBP of EOB-MRI. H&E staining of liver sections (magnification, x200; black scale bar, 100 µm). β-catenin and GS staining of liver tissue was performed to evaluate Wnt/β-catenin mutations (magnification, x200; black scale bar, 100 µm). EOB-MRI, gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid-enhanced magnetic resonance imaging; GS, glutamine synthetase; HBP, hepatobiliary phase; H&E, hematoxylin and eosin.

Kaplan-Meier estimates of OS and PFS in iso-high-intensity and low-intensity groups during HBP. Significant differences in OS and PFS were determined by log-rank analysis. OS, overall survival; PFS, progression-free survival; HBP, hepatobiliary phase.

Best percentage change in iso-high-intensity and low-intensity groups during HBP. Significant differences in the values of the best percentage change between groups were examined by Mann-Whitney U-test. HBP, hepatobiliary phase.

Characteristics of patients in the iso-high-intensity and low-intensity groups of HBP in EOB-MRI.

Characteristic All Iso-high-intensity group Low-intensity group P-value
Number 52 9 43  
Age, years 73 (68-79.75) 82 (75-87) 73 (68-78) 0.686
Sex, M/F 36/16 7/2 29/14 0.53
Etiology       0.3
     HCV 23 (44.2%) 1 (11.1%) 22 (51.2%)  
     HBV 10 (19.2%) 2 (22.2%) 8 (18.6%)  
     Alcohol 9 (17.3%) 2 (22.2%) 7 (16.3%)  
     AIH/PBC 2 (3.8%) 0 (0%) 2 (4.7%)  
     Cryptogenic 8 (15.5%) 4 (44.5%) 4 (9.2%)  
Max tumor size, cm 2.7 (1.7-4.9) 6.2 (3.25-8.35) 2.5 (1.6-3.9) 0.0004
Size of intrahepatic lesion >3 cm 24 (46.2%) 7 (77.8%) 17 (39.5%) 0.0364
Number of intrahepatic lesions >5 31 (59.6%) 5 (55.6%) 26 (60.4%) 0.7849
MVI positive 11 (21.2%) 1 (11.1%) 10 (23.3%) 0.69
EHS positive 12 (23.1%) 1 (11.1%) 11 (25.6%) 0.29
Child-Pugh score       0.63
     5A 29 (55.8%) 6 (72.7%) 23 (53.5%)  
     6A 13 (25%) 1 (11.1%) 12 (27.9%)  
     >7 10 (19.2%) 2 (22.2%) 8 (18.6%)  
Albumin 3.65 (3.3-4.1) 3.7 (3.4-4.1) 3.6 (3.3-4.2) 0.79
Total bilirubin 0.8 (0.6-1.2) 1.1 (0.8-2.3) 0.8 (0.6-1.1) 0.0068
BCLC       0.118
     A 7 (13.5%) 2 (22.2%) 5 (11.6%)  
     B 27 (51.9%) 4 (44.4%) 23 (53.5%)  
     C D 18 (34.6%) 3 (33.4%) 15 (34.9%)  
Tumor marker        
     AFP (ng/ml) 10.1 (3.58-188.88) 6.3 (3.3-6054.8) 10.3 (4.1-201.8) 0.692
     PIVKA-II (mAU/ml) 181.5 (32-3390) 938 (26.5-31832.5) 140 (32-18112) 0.0137
LEN dose       0.5604
     12 mg 4 (7.7%) 0 (0%) 4 (9.3%)  
     8 mg 27 (51.9%) 4 (44.4%) 23 (53.4%)  
     4 mg 21 (40.4%) 5 (54.6%) 16 (37.2%)  

Data are expressed as the median and interquartile range, or as numbers and percentages (%). EOB-MRI, gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid-enhanced magnetic resonance imaging; HCV, hepatitis C; HBV, hepatitis B; AIH, autoimmune hepatitis; PBC, primary biliary cholangitis; MVI, macroscopic portal vein invasion; EHS, extrahepatic spread; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein; PIVKA-II, vitamin K absence or antagonist-II; LEN, lenvatinib.

Relationship between Wnt/β-catenin mutations and signal intensity in the HBP of EOB-MRI in 13 patients.

Case Group Age, years Sex Etiology β-catenin GS
     1 iso-high 82 M ALC Positive Positive
     2 iso-high 58 F HBV Negative Positive
     3 iso-high 83 M NBNC Negative Positive
     4 iso-high 87 M NBNC Positive Positive
     5 Low 68 M HBV Negative Negative
     6 Low 80 M AIH Positive Positive
     7 Low 75 M HBV Positive Positive
     8 Low 59 M ALC Negative Negative
     9 Low 52 M HBV Positive Positive
10 Low 76 M HCV Negative Negative
11 Low 71 M HCV Negative Negative
12 Low 78 M HCV Negative Negative
13 Low 80 M ALC Negative Negative

HBP, hepatobiliary phase; EOB-MRI, gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid-enhanced magnetic resonance imaging; ALC, alcohol; GS, glutamine synthetase.

Comparison of the response to lenvatinib between the EOB iso-high-intensity group and low-intensity group (patient analysis).

LEN effectiveness Iso-high-intensity group, n=9 (%) Low-intensity group, n=43 (%) P-value
Overall response     0.14
     CR 0 (0) 2 (4.7)  
     PR 3 (33.3) 11 (25.6)  
     SD 2 (22.3) 13 (30.2)  
     PD 4 (44.4) 17 (39.5)  
ORR (CR+PR) 3 (33.3) 13 (30.2) 0.62
DCR (CR+PR+SD) 5 (55.6) 26 (60.5) 0.45

EOB, gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid; LEN, lenvatinib; CR, complete response; PR, partial response; SD, stable disease; PD, progression disease; DCR, disease control rate; ORR, objective response rate.

Comparison of the response to lenvatinib between the EOB iso-high-intensity group and low-intensity group (nodule analysis).

LEN effectiveness Iso-high-intensity group, n=14 (%) Low-intensity group, n=126 (%) P-value
Overall response     0.85
     CR 0 (0) 16 (12.7)  
     PR 4 (28.6) 21(16.7)  
     SD 9 (64.3) 57 (45.2)  
     PD 1 (7.1) 32 (25.4)  
ORR (CR+PR) 4 (28.6) 35 (27.8) 0.73
DCR (CR+PR+SD) 13 (92.9) 92 (73.0) 0.39

EOB, gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid; LEN, lenvatinib; CR, complete response; PR, partial response; SD, stable disease; PD, progression disease; ORR, objective response rate; DCR, disease control rate.